David A Moreno

USPTO Granted Patents = 39 (Patent Applications = 8)

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 13 (Patent Applications = 22)

Average Co-Inventor Count = 11.6

ph-index = 6

Forward Citations = 126(Granted Patents)

Location History:

Centennial, CO (US) (2022 - 2023)
Erie, CO (US) (2023)
Boulder, CO (US) (2012 - 2024)
Indianapolis, IN (US) (2024)

Company Filing History:

Eli Lilly and Company

patents

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

39 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12351571 - Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases (2025-07-08),

2. 12303509 - Compounds for the treatment of BRAF-associated diseases and disorders (2025-05-20),

3. 12180207 - Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases (2024-12-31),

4. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),

5. 11964988 - Fused heterocyclic compounds as RET kinase inhibitors (2024-04-23),

6. 11851434 - Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors (2023-12-26),

7. 11807651 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2023-11-07),

8. 11802127 - 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors (2023-10-31),

9. 11691973 - 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors (2023-07-04),

10. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),

11. 11634409 - Compounds for the treatment of BRAF-associated diseases and disorders (2023-04-25),

12. 11603374 - Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors (2023-03-14),

13. 11524963 - Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors (2022-12-13),

14. 11472802 - Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors (2022-10-18),

15. 11414404 - Compounds for the treatment of BRAF-associated diseases and disorders (2022-08-16),

Title: David A Moreno: Pioneering Innovations in the Field of Technology

Introduction:

David A Moreno, a distinguished inventor based in Boulder, CO, is renowned for his passion for innovation and his relentless dedication to creating a better world through his groundbreaking inventions. With a portfolio comprising 35 patents, Moreno stands as a true pioneer in the field of technology.

Latest Patents:

Among his recent patents are "Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors" and "Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors." These compounds, designed as inhibitors of RET kinase, hold immense promise in the treatment and prevention of various diseases associated with RET kinase activity.

Career Highlights:

Throughout his career, Moreno has showcased a penchant for pushing the boundaries of technological advancement. Having worked at esteemed companies such as Array Biopharma Inc. and Genentech, Inc., Moreno has consistently demonstrated his innovative prowess in developing solutions that address critical medical needs.

Collaborations:

A collaborative spirit lies at the core of Moreno's success. Working alongside accomplished peers like Li Ren and James F Blake, Moreno has been able to leverage collective expertise to drive forward transformative innovations in the realm of technology and healthcare.

Conclusion:

In conclusion, David A Moreno's remarkable journey as an inventor underscores his unwavering commitment to driving positive change through innovation. His trailblazing work in developing novel technologies for disease treatment has cemented his legacy as a visionary in the field of technology.

This text is generated by artificial intelligence and may not be accurate.